Fig. 6
From: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer
The anti-tumor and cachexia attenuating effects of R848 require stromal TLR7. Male TLR7 hemizygous null (TLR7KO) mice were implanted with TLR7 intact KxPxCx, then randomized to R848 or vehicle as previously described (a). Tumor size (b) was increased following R848 in this context, with representative histology shown in (d). Food intake (plotted as a function of time in d and as cumulative averages in e) and body weight (f) were both more severely affected during cachexia stage R848 treatment when TLR7 was absent in host tissues but present in neoplastic cells. This was accompanied by lean mass loss (g), no further changes in adipose wasting (h), skeletal muscle catabolism (i), cardiac muscle catabolism (j), and lack of splenic response to treatment (k). Statistical analyses were performed using two-way ANOVA during the cachexia stage to test for main effects of tumor and treatment, and the interaction thereof, with multiple-comparisons tests for main column effects. Values represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001
